[Dalton Transactions] Based on the pharmacological importance of diosgenin, the obtained derivatives were exposed to study their effect on breast cancer cells where they significantly reduced the growth of cancer cells and left non-malignant breast epithelial cells unaffected.
[Journal of Experimental & Clinical Cancer Research] The authors evaluated if kinases could be new targets for the treatment of luminal primary and metastatic breast cancers.
[ACS Applied Bio Materials] Scientists described the use of two chemical modifications, incorporating a neuropilin receptor agonist peptide and a hypoxia-responsive lipid for targeting and release of an encapsulated drug from bovine milk exosomes toTNBC cells.
[Oncogenesis] The authors investigated the correlation between different “omics” datasets and to define the new important key pathway and upstream regulators in breast cancer.
[Nature Reviews Gastroenterology & Hepatology] Expanding preclinical and clinical literature from PDAC and other oncological indications identifies novel approaches through which radiation therapy–immunotherapy combinations could improve local and systemic disease control in patients with PDAC.
[US FDA] The US FDA approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.